Prescription drug · ANDA
Icosapent Ethyl NDC 16714-636
Icosapent ethyl 1 g/1 · Capsule · Oral · Northstar Rx LLC
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 16714-636-01 | 16714063601 | 120 CAPSULE in 1 BOTTLE (16714-636-01)Marketed from Jul 1, 2025 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Icosapent Ethyl
- Generic name (nonproprietary)
- icosapent ethyl
- Active ingredients
- Icosapent ethyl — 1 g/1
- Dosage form
- Capsule
- Route
- Oral
- Labeler
- Northstar Rx LLC
- Product type
- Prescription drug
- Marketing category
- ANDA — Abbreviated New Drug Application (generic)Application ANDA 216811
- Marketing start
- Listing expires
- Identifiers
- Product ID 16714-636_ad34781b-7624-4344-a31f-83ef471da07bSPL ID ad34781b-7624-4344-a31f-83ef471da07bSPL set ID b5b0b1ae-29ab-43a5-9e6d-24374d961399RxCUI 1304979UNII 6GC8A4PAYHUPC 0316714636016
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N416714063601followed by a unit qualifier and the quantityPackage 16714-0636-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
Icosapent ethyl capsules are indicated: as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (≥ 500 mg/dL) hypertriglyceridemia. Limitations of Use: The effect of icosapent ethyl capsules on the risk for pancreatitis in patients with severe hypertriglyceridemia has not been determined. Icosapent ethyl capsules are an ethyl ester of eicosapentaenoic acid (EPA) indicated: as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (≥ 500 mg/dL) hypertriglyceridemia. (1) Limitations of Use: The effect of icosapent ethyl capsules on the risk for pancreatitis in patients with severe hypertriglyceridemia has not been determined. (1)…
Excerpt only. Read the full label for complete information.
Other NDCs under ANDA 216811
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Icosapent Ethyl | Icosapent ethyl 1 g/1 | CapsuleOral | Bryant Ranch Prepack | 71335-2989 |
| Icosapent Ethyl | Icosapent ethyl .5 g/1 | CapsuleOral | Camber Pharmaceuticals, Inc. | 31722-298 |
| Icosapent Ethyl | Icosapent ethyl 1 g/1 | CapsuleOral | Camber Pharmaceuticals, Inc. | 31722-299 |
| Icosapent Ethyl | Icosapent ethyl .5 g/1 | CapsuleOral | XLCare Pharmaceuticals, Inc. | 72865-289 |
| Icosapent Ethyl | Icosapent ethyl 1 g/1 | CapsuleOral | XLCare Pharmaceuticals, Inc. | 72865-290 |
- openFDA data updated
Med-Code stores this record for up to 24 hours before requesting it again.
Reference information only. Verify codes and billing rules against the applicable payer and official source before submitting a claim. How Med-Code handles data.